The estimated Net Worth of Uwe E Reinhardt is at least $189 Thousand dollars as of 29 November 2007. Uwe Reinhardt owns over 9,000 units of abrdn Life Sciences Investors stock worth over $75,000 and over the last 17 years Uwe sold HQL stock worth over $113,580.
Uwe has made over 1 trades of the abrdn Life Sciences Investors stock since 2007, according to the Form 4 filled with the SEC. Most recently Uwe sold 9,000 units of HQL stock worth $113,580 on 29 November 2007.
The largest trade Uwe's ever made was selling 9,000 units of abrdn Life Sciences Investors stock on 29 November 2007 worth over $113,580. On average, Uwe trades about 900 units every 0 days since 2007. As of 29 November 2007 Uwe still owns at least 5,000 units of abrdn Life Sciences Investors stock.
You can see the complete history of Uwe Reinhardt stock trades at the bottom of the page.
Uwe's mailing address filed with the SEC is ONE BOSTON SCIENTIFIC PLACE, , NATICK, MA, 01760-1537.
Over the last 20 years, insiders at abrdn Life Sciences Investors have traded over $26,240 worth of abrdn Life Sciences Investors stock and bought 920,961 units worth $12,356,710 . The most active insiders traders include Capital Management, L.P.Wei..., Daniel R Omstead, and Jeffrey Allen Bailey. On average, abrdn Life Sciences Investors executives and independent directors trade stock every 129 days with the average trade being worth of $242,880. The most recent stock trade was executed by Bill Maher on 23 August 2024, trading 650 units of HQL stock currently worth $9,991.
tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
abrdn Life Sciences Investors executives and other stock owners filed with the SEC include: